Press Release - October 1, 2021
Heidelberg, Germany, October 01, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three abstracts with preclinical data of its innate cell engagers have been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 10-14, 2021.
Title: Tetravalent, bispecific innate cell engager AFM24 enhances macrophage mediated tumor cell phagocytosis
Abstract ID: 880
Authors: Sheena Pinto, Susanne Wingert, Jens Pahl, Armin Beez, Sabrina Purr, Uwe Reusch, Arndt Schottelius and Joachim Koch
Title: Enhanced antibody-mediated phagocytosis and antibody-mediated cell cytotoxicity using tetravalent, bispecific innate cell engagers (ICE®) in 3D spheroids
Abstract ID: 881
Authors: Sheena Pinto, Savannah Jackson, Julia Knoch, Christian Breunig, Arndt Schottelius and Joachim Koch
Title: The bispecific innate cell engagers AFM13 (CD30/CD16A) and AFM24 (EGFR/CD16A) increase the fraction of tumor target-responsive NK cells and boost serial killing
Abstract ID: 894
Authors: Chiara Zambarda, Karolin Guldevall, Christian Breunig, Damien Toullec, Jacopo Fontana, Sheena Pinto, Jens Pahl, Susanne Wingert, Joachim Koch and Björn Önfelt
The full abstracts will be released on November 9, 2021 at 8 a.m. EST.
For more details about the SITC Virtual Annual Meeting please visit: https://www.sitcancer.org/2021/home.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com.
Alex Fudukidis
Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail: M.Sandin@affimed.com
Tel: +1 (484) 888-8195